Brancaster Pharma Issues Class 4 Medicines Defect Notification for Benzylpenicillin
The Class 4 Medicines Defect Notification regarding Brancaster Pharma's Benzylpenicillin benzathine highlights potential regulatory compliance issues that could affect the company's market position. Monitoring the regulatory response is crucial for understanding the implications for product safety and market access.
Company
Brancaster Pharma Limited
Asset
Brancaster
Indication
Infectious Disease / Antibiotic
Status
Under Review
Signal Score
6.8
Signal assessment
Signal strength
moderate
Confidence level
moderate
Strategic implication
The Class 4 Medicines Defect Notification regarding Brancaster Pharma's Benzylpenicillin benzathine highlights potential regulatory compliance issues that could affect the company's market position. Monitoring the regulatory response is crucial for understanding the implications for product safety and market access.
Why it matters
The Class 4 Medicines Defect Notification regarding Brancaster Pharma's Benzylpenicillin benzathine highlights potential regulatory compliance issues that could affect the company's market position. Monitoring the regulatory response is crucial for understanding the implications for product safety and market access.
What changed
Safety Signal
Analysis
Brancaster Pharma Limited reported that certain batches of Benzylpenicillin benzathine were released with an outdated Patient Information Leaflet.
The Class 4 Medicines Defect Notification regarding Brancaster Pharma's Benzylpenicillin benzathine highlights potential regulatory compliance issues that could affect the company's market position. Monitoring the regulatory response is crucial for understanding the implications for product safety and market access.
Follow-up on regulatory actions taken by the MHRA and any communications from Brancaster Pharma regarding corrective measures.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.